Unveiling Biomarkers and Therapeutic Targets in Systemic Sclerosis and Lupus Erythematosus Through Transcriptomic...

Area of Science:

• Immunology
• Genomics
• Molecular Biology

Background:

• Systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) are distinct autoimmune diseases with complex molecular underpinnings.
• Understanding their shared and unique molecular profiles is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate molecular differences and commonalities between SSc and SLE using RNA-sequencing (RNA-seq) data.
• To identify unique biomarkers, shared pathways, and potential therapeutic targets for SSc and SLE.

Main Methods:

• Analysis of RNA-seq data from 10 SSc patients and 24 SLE patients (treatment-naïve).
• Differential gene expression analysis using DESeq2.
• Functional and pathway enrichment analyses, including comparative analyses.

Main Results:

• Identified 2055 differentially expressed genes (DEGs) between SSc patients and controls.
• Found significant downregulation of the shared gene RGS5 in both SLE and SSc, more pronounced in SSc.
• Observed upregulation of EGR1 in SSc, and BLK, ITGAM, IFNG in SLE. Identified key hub genes (e.g., AP3D1, FTX) potentially involved in both diseases.

Conclusions:

• RGS5 may serve as a shared biomarker for vascular dysfunction in SSc and SLE.
• EGR1 and BLK are potential therapeutic targets for SSc and SLE, respectively.
• The study provides insights into distinct and overlapping gene expression signatures, laying groundwork for future targeted treatments requiring validation.